KR100797985B1 - Liquid crystal membrane emulsion composition and preparation method thereof - Google Patents
Liquid crystal membrane emulsion composition and preparation method thereof Download PDFInfo
- Publication number
- KR100797985B1 KR100797985B1 KR1020050126658A KR20050126658A KR100797985B1 KR 100797985 B1 KR100797985 B1 KR 100797985B1 KR 1020050126658 A KR1020050126658 A KR 1020050126658A KR 20050126658 A KR20050126658 A KR 20050126658A KR 100797985 B1 KR100797985 B1 KR 100797985B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- weight
- liquid crystal
- crystal film
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 239000004973 liquid crystal related substance Substances 0.000 title claims abstract description 58
- 239000000839 emulsion Substances 0.000 title claims abstract description 29
- 239000012528 membrane Substances 0.000 title description 3
- 238000002360 preparation method Methods 0.000 title 1
- 239000003921 oil Substances 0.000 claims abstract description 36
- 239000003925 fat Substances 0.000 claims abstract description 29
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims abstract description 27
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 23
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 20
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 20
- 229930195729 fatty acid Natural products 0.000 claims abstract description 20
- 239000000194 fatty acid Substances 0.000 claims abstract description 20
- 239000000787 lecithin Substances 0.000 claims abstract description 20
- 235000010445 lecithin Nutrition 0.000 claims abstract description 20
- 229940067606 lecithin Drugs 0.000 claims abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 17
- -1 glycerin fatty acid ester Chemical class 0.000 claims abstract description 17
- 235000011187 glycerol Nutrition 0.000 claims abstract description 17
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims abstract description 14
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims abstract description 12
- 229960002446 octanoic acid Drugs 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 150000004667 medium chain fatty acids Chemical class 0.000 claims abstract description 11
- 238000002156 mixing Methods 0.000 claims abstract description 11
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims abstract description 8
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000005639 Lauric acid Substances 0.000 claims abstract description 4
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims abstract description 3
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 36
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 26
- 235000019197 fats Nutrition 0.000 claims description 25
- 235000021342 arachidonic acid Nutrition 0.000 claims description 18
- 229940114079 arachidonic acid Drugs 0.000 claims description 18
- ACXGEQOZKSSXKV-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O.CCCCCCCC(O)=O ACXGEQOZKSSXKV-UHFFFAOYSA-N 0.000 claims description 13
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 11
- UWLPCYBIJSLGQO-UHFFFAOYSA-N dodecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCC(O)=O UWLPCYBIJSLGQO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229940049964 oleate Drugs 0.000 claims description 11
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 claims description 4
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- YEBDWAHEIMUJQT-ZLCLUPBPSA-N (5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O.CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YEBDWAHEIMUJQT-ZLCLUPBPSA-N 0.000 claims description 2
- HABLENUWIZGESP-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O.CCCCCCCCCC(O)=O HABLENUWIZGESP-UHFFFAOYSA-N 0.000 claims description 2
- 235000020664 gamma-linolenic acid Nutrition 0.000 claims 3
- 229960002733 gamolenic acid Drugs 0.000 claims 3
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- WLGSIWNFEGRXDF-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O.CCCCCCCCCCCC(O)=O WLGSIWNFEGRXDF-UHFFFAOYSA-N 0.000 claims 1
- 230000003647 oxidation Effects 0.000 abstract description 10
- 238000007254 oxidation reaction Methods 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 8
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 238000004945 emulsification Methods 0.000 abstract description 5
- 239000004615 ingredient Substances 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 29
- 230000000052 comparative effect Effects 0.000 description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 235000013350 formula milk Nutrition 0.000 description 7
- 239000013078 crystal Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 244000294411 Mirabilis expansa Species 0.000 description 1
- 235000015429 Mirabilis expansa Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 235000013536 miso Nutrition 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 238000010428 oil painting Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000021085 polyunsaturated fats Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003815 prostacyclins Chemical class 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019511 tuna Nutrition 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/10—Foods or foodstuffs containing additives; Preparation or treatment thereof containing emulsifiers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/20—Ingredients acting on or related to the structure
- A23V2200/222—Emulsifier
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1842—Lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1882—Polyunsaturated fatty acids
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Edible Oils And Fats (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
본 발명은 액정막 유화 조성물 및 그 제조방법에 관한 것으로, 보다 상세하게는 (a) 고도불포화지방산을 함유하는 유지 10 내지 80 중량부; (b) 카프로산(caproic acid), 카프릴산(caprylic acid), 카프르산(capric acid), 라우르산(lauric acid) 및 이들의 혼합물로 이루어진 군으로부터 선택된 중쇄지방산을 함유하는 유지 10 내지 80 중량부; (c) 인지질이 25 내지 85 중량% 함유되어 있는 레시틴 1 내지 10 중량부; 및, (d) 글리세린지방산에스테르 1 내지 15 중량부를 포함하는 액정막 유화 조성물을 제공한다.The present invention relates to a liquid crystal film emulsion composition and a method for producing the same, and more specifically, (a) 10 to 80 parts by weight of a fat or oil containing a polyunsaturated fatty acid; (b) fats and oils containing medium-chain fatty acids selected from the group consisting of caproic acid, caprylic acid, capric acid, lauric acid and mixtures thereof; 80 parts by weight; (c) 1 to 10 parts by weight of lecithin, containing 25 to 85% by weight of phospholipids; And (d) 1 to 15 parts by weight of glycerin fatty acid ester.
본 발명의 조성물은 고도불포화지방산을 함유하는 유지가 미세액정막 내에 봉입되어, 산화안정성이 확보되어 장기저장이 가능하고, 취급이 용이하다. 또한, 분산성이 증대되어 식품에 첨가시 다른 성분과의 혼합이 용이하며, 섭취시 체내에서 보다 잘 분산되어 흡수속도를 증가시킬 수 있다. The composition of the present invention is a fat or oil containing polyunsaturated fatty acid is encapsulated in the micro-liquid crystal film, the oxidation stability is ensured, long-term storage is possible, and easy handling. In addition, the dispersibility is increased to facilitate the mixing with other ingredients when added to food, it can be more dispersed in the body when ingested to increase the absorption rate.
고도불포화지방산, 액정막, 조성물, 유화 Polyunsaturated Fatty Acid, Liquid Crystal Film, Composition, Emulsification
Description
도 1은 실시예 1에 따른 조성물 및 그 미세액정막의 현미경 사진이다.1 is a micrograph of a composition according to Example 1 and a microliquid crystal film thereof.
본 발명은 액정막 유화 조성물 및 그 제조방법에 관한 것으로, 더욱 상세하게는 고도불포화지방산을 함유하는 유지를 미세액정막 내에 봉입시켜 산화를 방지하고, 보존 안정성 및 분산성을 증가시켜, 식품, 특히 유아용 조제분유에 용이하게 첨가할 수 있도록 한 액정막 유화 조성물 및 그 제조방법에 관한 것이다. The present invention relates to a liquid crystal film emulsifying composition and a method of manufacturing the same, and more particularly, a fat or oil containing polyunsaturated fatty acid is encapsulated in a microliquid crystal film to prevent oxidation, to increase storage stability and dispersibility, The present invention relates to a liquid crystal film emulsion composition and a method for producing the same which can be easily added to infant formula.
최근에 고도불포화지방산이 여러 가지 생리작용을 가진 것으로 보고 되고 있고, 그 영양학적, 의학적 가치가 밝혀지면서 이에 대한 관심이 증가하고 있다. 특히 아라키돈산(arachidonic acid)은 자궁근 수축, 이완 작용, 혈관 확장, 혈압 강하 작용 등, 강력하며 다채로운 생리 활성을 갖는 프로스타글란딘, 트롬복산, 프로스타시클린, 로이코톨루엔 등의 전구 물질이라 하여 근래 주목받고 있는데, 특히 유아의 발육에 필요한 성분으로서 DHA와 함께 급속히 연구가 진행되고 있다. 즉 Lanting들은 생후 3주 이상 모유로 키운 유아와 육아용 분유로 키운 유아를 9세까지 추적 조사하여 행동면 등에서 뇌신경의 작은 장해의 발생률을 검토한 결과, 분유로 키운 어린이의 뇌 장해 발생률은 모유로 키운 어린이의 2배라고 보고하였다[LANCET, Vo.344, 1319-1322(1994)]. 이 놀라운 결과는 모유에는 존재하지만 육아용 분유에는 거의 존재하지 않는 DHA 및 아라키돈산 등의 장쇄 불포화 지방산이 뇌의 발달에 관여했기 때문일 것이라고 추측되고 있다. 분유를 유아에게 있어서 이상적인 영양이라고 여겨지는 모유와 근접시키는 연구가 이전부터 이루어져 왔으나, 지금까지 이러한 모유의 기본적인 영양소, 비타민, 미네랄 등과 감염 방어 작용의 해명에 중점이 놓여져 왔다. 그러나, 최근에는 장쇄 다가 불포화 지방산의 뇌에 대한 영향에도 관심이 향해지고 있다. 이 밖에도 근래 장쇄 불포화 지방산이 신생아의 뇌 및 망막의 발달에 관계하고 있을 것이라는 결과가 계속해서 보고되어, 미숙아 및 신생아 영양의 영역에서 뜨거운 화제로서 주목받고 있다.Recently, polyunsaturated fatty acids have been reported to have various physiological effects, and as their nutritional and medical value is revealed, interest in them has increased. In particular, arachidonic acid (arachidonic acid) is a precursor of prostaglandins, thromboxanes, prostacyclins, leucotoluenes, etc., which have strong and diverse physiological activities such as uterine muscle contraction, relaxation, vasodilation, and blood pressure lowering effects. In particular, research is being conducted rapidly with DHA as an ingredient necessary for the development of infants. In other words, the lanting conducted a follow-up survey of infants who had been breast-fed for 3 weeks or older and infants who had been fed with infant formula until the age of 9, and examined the incidence of minor brain disorders in terms of behavior. It was reported to be twice the size of raised children [LANCET, Vo.344, 1319-1322 (1994)]. This surprising result is presumed to be due to the development of long-chain unsaturated fatty acids, such as DHA and arachidonic acid, which are present in mother's milk but are rarely present in parenting milk. Previous studies have been conducted to bring formula into close proximity to breastmilk, which is considered the ideal nutrition for infants, but until now, the focus has been on the clarification of infection defenses such as the basic nutrients, vitamins and minerals of breast milk. However, in recent years, attention has also been directed to the effect of long-chain polyunsaturated fatty acids on the brain. In addition, the results of the recent long-chain unsaturated fatty acids related to the development of the brain and retina of the newborn has been reported continuously, attracting attention as a hot topic in the field of nutrition of premature infants and newborns.
한편, 도코사헥사엔산(docosahexaenoic acid:이하 DHA라 칭함) 및 아라키돈산(arachidonic acid:이하 ARA라 칭함)과 같은 불포화지방산은 뇌세포의 구성성분으로서 출생시부터 초기 아동기 동안 두뇌발달을 촉진하여 발달과 기억, 학습기능을 향상시킬 뿐만 아니라, 성장 촉진, 신경계의 눈의 반사능 향상 및 암 예방 등에도 관여하는 것으로 알려져 있다. On the other hand, unsaturated fatty acids such as docosahexaenoic acid (hereinafter referred to as DHA) and arachidonic acid (hereinafter referred to as ARA) are components of brain cells that promote brain development from birth to early childhood. In addition to improving development, memory and learning functions, it is known to be involved in promoting growth, improving the reflexes of the nervous system and preventing cancer.
이와 같은 탁월한 기능을 갖고 있는 고도불포화지방산을 함유하는 유지를 기능성 식품 및 의약품에 이용하려는 연구가 활발히 진행되고 있으며, 이미 유아용 조제분유, 된장, 참치통조림 등의 제품에 이용되고 있을 뿐만 아니라, EPA 함량이 높은 어유의 정제농축물이 건강기능식품으로 이용되고 있다. Research into active use of fatty acids containing polyunsaturated fatty acids with such excellent functions in functional foods and medicines has been actively conducted, and it is already being used in products such as infant formula, miso, and canned tuna. This high fish oil refined concentrate is used as a dietary supplement.
그러나, 고도불포화지방산을 다량으로 함유하는 유지는 산소나 광선에 불안정하여 저장 중 쉽게 산화하여 바람직하지 않은 냄새를 발생시키며, 그 자체의 독특한 비린내가 문제가 되어 안정성 향상을 위한 연구가 다양하게 이루어지고 있다. However, fats and oils containing a large amount of polyunsaturated fatty acids are unstable to oxygen or light and oxidize easily during storage, causing undesirable odors, and their unique fishy becomes a problem. have.
이러한 안정성 향상을 위한 종래의 기술로, 전분, 알긴산, 멜라민, 에칠셀룰로스, 키토산 등을 벽재로 사용하여 눈에 보일 만큼의 거대캡슐이나 20 마이크로 이상의 미세캡슐을 제조하거나, 기능성 물질을 베이스 처방 내에서 필요 이상으로 고농도 처방하여 유통기간 내 손실분을 감안하거나 하이루론산, 토코페롤, 비타민씨 등과 같은 안정화제나 항산화제, 첨가제 등을 고농도로 배합하거나 또는 영양성분의 흡수전달이 용이하도록 리포좀, 실리콘 등의 코팅제를 다량으로 배합하는 방법을 사용하였다. 그러나, 종래의 방법은 기능성 물질이나 첨가된 안정제, 코팅제, 항산화제 등이 원료 자체의 안정도는 일정하다고 할 수 있으나, 일단 식품, 의약품 등의 제형에 첨가되면 시간의 경과 및 가혹조건에 따른 색상, 점도, pH 등의 물성의 경시변화가 심하게 나타나는 문제점이 있어 상품 자체에 이상을 초래하게 되는 문제점이 야기된다. As a conventional technique for improving the stability, using starch, alginic acid, melamine, ethylcellulose, chitosan, etc. as a wall to produce a visible giant capsule or microcapsules of 20 micro or more, or a functional substance in the base prescription Prescribe higher concentrations than necessary to account for losses in the shelf life, or formulate high concentrations of stabilizers, antioxidants, and additives such as hyaluronic acid, tocopherol, and vitamin C, or apply coatings such as liposomes and silicones to facilitate the absorption and delivery of nutrients. The method of compounding in large quantities was used. However, in the conventional method, the stability of the raw material itself may be consistent with the functional substances, the stabilizer, the coating agent, the antioxidant, and the like, but once added to the formulation of food, pharmaceuticals, etc., the color according to the lapse of time and harsh conditions, There is a problem that changes in physical properties such as viscosity, pH, etc. are severely exhibited, which causes problems in the product itself.
한편, 액정은 분자간의 규칙적인 배향에 의하여 액상보다 상대적으로 적은 분자 운동성을 가지며, 이로 인해 점도 및 유동성 면에서는 액체처럼 행동하나, 빛 의 산란과 반사 같은 물성에 있어서는 결정성의 물성을 나타내는 등 독특한 성질을 가지고 있다. 이와 같은 상대적으로 적은 분자간 분자 운동성으로 인하여, 액정은 화장품, 의약품 등의 분야에서 불안정한 물질의 안정성을 향상시키는 특성을 나타낸다. On the other hand, liquid crystals have relatively less molecular mobility than liquid phases due to their regular orientation between molecules, and thus behave like liquids in terms of viscosity and fluidity, but exhibit crystalline properties in physical properties such as scattering and reflection of light. Have Due to such relatively low intermolecular mobility, the liquid crystal exhibits a property of improving the stability of an unstable substance in the fields of cosmetics and pharmaceuticals.
이러한 액정유화의 가장 큰 특징은 피부 지질과 매우 유사한 라멜라 구조막을 가지고 있어 피부친화력과 보습 유지력이 일반 유화에 비해 월등하게 뛰어나다는 것이다. 또한 액정 유화를 실시할 경우 종래의 유상/수상, 수상/유상 유화에 비해 현저히 높은 생리활성물질 안정화 동시에 생리활성물질의 서방성을 동시에 만족시키는 이점이 있다. The biggest feature of these liquid crystal emulsifications is that it has a lamellar structure membrane that is very similar to skin lipids, so that the skin affinity and moisturizing retention properties are superior to those of general emulsions. In addition, when the liquid crystal emulsification is carried out, there is an advantage of stabilizing the bioactive substance at the same time as the stabilization of the bioactive substance significantly higher than the conventional oil phase / water phase, water phase / oil phase emulsification.
그러나, 산화에 불안정한 물질인 고도불포화지방산을 안정한 형태로 미세액정막에 봉입한 조성물은 없었다. However, there was no composition in which the polyunsaturated fatty acid, which is a material that is unstable in oxidation, was encapsulated in a microliquid film in a stable form.
상기와 같은 문제점을 해결하기 위한 것으로서, 본 발명의 목적은 산화 및 극성의 변화가 심하여 불안정한 고도불포화지방산을 안정화시켜 기능성을 향상하고, 식품에 첨가시 분산성을 증대시킬 수 있는 초미세사이즈의 액정막 유화 조성물을 제공하는 것이다. In order to solve the above problems, an object of the present invention is to improve the functionality by stabilizing unsaturated polyunsaturated fatty acid due to severe oxidation and polarity change, ultra-small liquid crystal that can increase the dispersibility when added to food It is to provide a film emulsion composition.
본 발명의 다른 목적은 상기 물성을 갖는 액정막 유화 조성물을 제조하는 방법을 제공한다. Another object of the present invention to provide a method for producing a liquid crystal film emulsion composition having the above properties.
상기 목적을 달성하기 위하여, 본 발명은 (a) 고도불포화지방산을 함유하는 유지 10 내지 80 중량부; (b) 카프로산(caproic acid), 카프릴산(caprylic acid), 카프르산(capric acid), 라우르산(lauric acid) 및 이들의 혼합물로 이루어진 군으로부터 선택된 중쇄지방산을 함유하는 유지 10 내지 80 중량부; (c) 인지질이 25 내지 85 중량% 함유되어 있는 레시틴 1 내지 10 중량부; 및, (d) 글리세린지방산에스테르 1 내지 15 중량부를 포함하는 액정막 유화 조성물을 제공한다. In order to achieve the above object, the present invention (a) 10 to 80 parts by weight of a fat containing polyunsaturated fatty acid; (b) fats and oils containing medium-chain fatty acids selected from the group consisting of caproic acid, caprylic acid, capric acid, lauric acid and mixtures thereof; 80 parts by weight; (c) 1 to 10 parts by weight of lecithin, containing 25 to 85% by weight of phospholipids; And (d) 1 to 15 parts by weight of glycerin fatty acid ester.
또한, 본 발명은 (1) (a) 고도불포화지방산을 함유하는 유지 10 내지 80 중량부; (b) 중쇄지방산을 함유하는 유지 10 내지 80 중량부; 및 (c) 인지질이 25 내지 85 중량% 함유되어 있는 레시틴 1 내지 10 중량부를 35 내지 40℃에서 혼합하고, 질소를 투입하면서 10 내지 20 분 동안 3000 내지 8000rpm으로 호모믹싱하는 단계; (2) 상기 단계에서 호모믹싱된 혼합물을 마이크로플루다이저 (microfludizer)에 통과시키는 단계; 및 (3) 상기 단계에서 마이크로플루다이저에 통과된 혼합물에 글리세린지방산에스테르 1 내지 15 중량부를 첨가하여 혼합하고, 20 내지 40분 동안 호모믹싱한 후 20 내지 30℃까지 냉각시키는 단계를 포함하는 액정막 유화 조성물의 제조방법을 제공한다.In addition, the present invention (1) (a) 10 to 80 parts by weight of fats and oils containing polyunsaturated fatty acids; (b) 10 to 80 parts by weight of fats and oils containing medium chain fatty acids; And (c) mixing 1 to 10 parts by weight of lecithin containing 25 to 85% by weight of phospholipid at 35 to 40 ° C., and homomixing at 3000 to 8000 rpm for 10 to 20 minutes while adding nitrogen; (2) passing the homomixed mixture in the step through a microfludizer; And (3) adding 1 to 15 parts by weight of glycerin fatty acid ester to the mixture passed through the microfluidizer in the above step, mixing, homomixing for 20 to 40 minutes, and then cooling to 20 to 30 ° C. It provides a method for producing a membrane emulsion composition.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 고도불포화지방산을 함유하는 유지를 사용함에 있어, 산화안정성을 확보하고, 식품에 첨가시 분산성을 증대시키기 위해 예의 연구한 결과, 고 도불포화지방산을 함유하는 유지를 미세액정막에 봉입시켜 액정 유화한 경우, 상대적으로 적은 분자간 분자 운동성으로 인하여, 고도불포화지방산의 안정성 및 분산성이 향상됨을 확인하고, 이를 토대로 본 발명을 완성하게 되었다. The present inventors have diligently investigated the use of fats and oils containing polyunsaturated fatty acids to ensure oxidative stability and to increase dispersibility when added to foods. In the case of liquid crystal emulsification, it was confirmed that the stability and dispersibility of the polyunsaturated fatty acid were improved due to relatively small intermolecular molecular mobility, and thus the present invention was completed.
본 발명의 액정막 유화 조성물은 (a) 고도불포화지방산을 함유하는 유지; (b) 중쇄지방산을 함유하는 유지; (c) 인지질이 25 내지 85 중량% 함유되어 있는 레시틴; 및 (d) 글리세린지방산에스테르를 포함한다. The liquid crystal film emulsion composition of this invention is (a) fats and oils containing polyunsaturated fatty acid; (b) fats and oils containing medium chain fatty acids; (c) lecithin containing 25 to 85% by weight of phospholipids; And (d) glycerin fatty acid esters.
본 발명에서 고도불포화지방산을 함유하는 유지는 미생물 유래 오일, 정제어유, 스쿠알렌, 대구간유, 대두유, 참깨유, 들깨유, 옥수수유, 해바라기유, 올리브유를 포함하는 식물성 유지 및 동물성 유지이다. 상기 고도불포화지방산은 유아 성장에 필수적인 DHA, EPA, 감마-리놀레산 또는 아라키돈산인 것이 바람직하며, 아라키돈산은 미생물로부터 수득하거나, 난황 또는 동물의 장기로부터 추출된 것을 사용할 수 있다. The fats and oils containing polyunsaturated fatty acids in the present invention are vegetable oils and animal fats and oils including microorganism derived oil, refined fish oil, squalene, cod liver oil, soybean oil, sesame oil, perilla oil, corn oil, sunflower oil, olive oil. The polyunsaturated fatty acid is preferably DHA, EPA, gamma-linoleic acid or arachidonic acid essential for infant growth, and arachidonic acid may be obtained from microorganisms or extracted from egg yolk or animal organs.
이때, 고도불포화지방산을 함유하는 유지의 함량은 10 내지 80 중량부인 것이 바람직한데, 그 함량이 10 중량부 미만이면, 첨가에 따른 효과가 미미하며, 80 중량부를 초과하는 경우, 초과투입에 따른 상승효과가 적어 경제적이지 못하다. At this time, the content of the oil containing polyunsaturated fatty acid is preferably 10 to 80 parts by weight, if the content is less than 10 parts by weight, the effect of the addition is insignificant, if it exceeds 80 parts by weight, the increase due to excess input It is not economical because it is small.
상기 중쇄지방산을 함유하는 유지는 중쇄지방산트리글리세라이드(Medium Chain Triglyceride, MCT) 오일로서, 중쇄지방산은 카프로산(caproic acid), 카프릴산(caprylic acid), 카프르산(capric acid), 라우르산(lauric acid) 및 이들의 혼합물로 이루어진 군으로부터 선택된 것을 사용하는 것이 바람직하며, 카프릴산 (caprylic acid)이 80% 이상 함유된 것을 사용하는 것이 산화 안정성 및 소화흡수면에서 가장 바람직하다. 이때, 중쇄지방산을 함유하는 유지의 함량은 10 내지 80 중량부인 것이 바람직한데, 그 함량이 10 중량부 미만이면, 첨가에 따른 효과가 미미하며, 80 중량부를 초과하는 경우, 초과투입에 따른 상승효과가 적어 경제적이지 못하다. The fat or oil containing the medium chain fatty acid is medium chain triglyceride (MCT) oil, the medium chain fatty acid is caproic acid (caproic acid), caprylic acid (caprylic acid), capric acid (capric acid), lauric Preference is given to using those selected from the group consisting of lauric acid and mixtures thereof, and those containing 80% or more of caprylic acid are most preferred in terms of oxidative stability and digestive absorption. At this time, the content of fats and oils containing medium chain fatty acid is preferably 10 to 80 parts by weight, if the content is less than 10 parts by weight, the effect of the addition is insignificant, if it exceeds 80 parts by weight, synergistic effect due to excess input Is less economical.
상기 인지질을 함유한 레시틴은 1차 액정막을 형성하는 기재로 작용한다. 이때, 인지질이 25 내지 85 중량% 함유되어 있는 레시틴은 1 내지 10 중량부 포함되는 것이 바람직하다. 레시틴의 함량이 1 중량부 미만이면, 충분한 액정막을 형성할 수 없어 2차 액정막 형성제인 글리세린지방산에스테르와 함께 액정막 형성이 어려우며, 10 중량부를 초과하면 추가에 따른 효과가 없어 경제적이지 못하다. The lecithin containing the phospholipid serves as a substrate for forming the primary liquid crystal film. At this time, it is preferable that 1 to 10 parts by weight of lecithin, which contains 25 to 85% by weight of phospholipids. When the content of lecithin is less than 1 part by weight, it is difficult to form a sufficient liquid crystal film, and thus it is difficult to form a liquid crystal film with glycerin fatty acid ester, which is a secondary liquid crystal film forming agent. If the content is more than 10 parts by weight, it is not economical.
여기서, 인지질은 유화제의 역할도 하여 미세액정막이 더욱 안정하게 형성되도록 한다. 상기 인지질의 함량은 25 내지 85 중량%가 바람직하며, 인지질의 함량이 25 중량% 보다 적으면 항산화 작용이 떨어지는 단점이 있다. Here, the phospholipid also serves as an emulsifier so that the microliquid crystal film is more stably formed. The content of the phospholipid is preferably 25 to 85% by weight, and when the content of the phospholipid is less than 25% by weight, there is a disadvantage in that antioxidant activity is lowered.
상기 글리세린지방산에스테르는 1차 액정막형성제인 인지질을 함유하는 레시틴과 함께 2차 액정막형성제의 역할을 하며, 강력한 액정막을 형성하여 고도불포화지방산을 외부와 차단하여 안정성을 극대화한다. The glycerin fatty acid ester plays a role of the secondary liquid crystal film forming agent together with the lecithin containing the phospholipid which is the primary liquid crystal film forming agent, and forms a powerful liquid crystal film to block the polyunsaturated fatty acid from the outside to maximize stability.
이때, 글리세린지방산에스테르는 글리세린모노라우레이트, 글리세린모노올 레이트, 폴리글리세린-2-올레이트, 폴리글리세린-2-스테아레이트, 및 이들의 혼합물로 이루어지는 군으로부터 선택된 것이 바람직하다. 글리세린지방산에스테르의 함량은 1 내지 15 중량부인 것이 바람직한데, 글리세린지방산에스테르의 함량이 1 중량부 미만이면, 액정막 형성이 어려우며, 15 중랑부를 초과하면 추가에 따른 효과가 없어 경제적이지 못하다. At this time, the glycerin fatty acid ester is preferably selected from the group consisting of glycerin monolaurate, glycerin monooleate, polyglycerine-2-oleate, polyglycerine-2-stearate, and mixtures thereof. It is preferable that the content of glycerin fatty acid ester is 1 to 15 parts by weight, but if the content of glycerin fatty acid ester is less than 1 part by weight, it is difficult to form a liquid crystal film.
본 발명의 조성물 중의 고도불포화지방산을 함유하는 유지는 액정막형성제에 의해 안정적으로 형성된 막 내부에 내포된다. 이러한 미세액정막은 외부의 자극과의 직접 접촉을 막아주기 때문에 산화에 약한 유지가 보호되고, 분산성이 증대되어 다른 식품에 첨가시 혼합이 용이하며, 체내에서 보다 잘 분산되어 흡수성이 증가된다. 또한 액정막의 상대적으로 적은 분자간 분자 운동성으로 인하여, 안정성이 향상된다. The fat or oil containing polyunsaturated fatty acid in the composition of the present invention is contained within the film stably formed by the liquid crystal film forming agent. Since the microliquid crystal film prevents direct contact with external stimuli, weak fats and oils are protected, and dispersibility is increased, and it is easy to mix when added to other foods. In addition, due to the relatively low intermolecular molecular mobility of the liquid crystal film, stability is improved.
도 1은 본 발명에 의한 미세액정막에 봉입된 조성물의 현미경 사진(배율 400X, 올림푸스 BX40 광학현미경)이다. 도 1에서 볼 수 있는 바와 같이, 미세액정막이 형성됨을 확인할 수 있다. 1 is a micrograph (magnification 400X, Olympus BX40 optical microscope) of a composition encapsulated in a microliquid crystal film according to the present invention. As can be seen in Figure 1, it can be seen that the fine liquid crystal film is formed.
이러한 액정막 내에 봉입된 조성물의 직경은 100 내지 300nm의 미세사이즈를 갖는 것이 바람직하다. 직경이 100nm 미만이면, 크기가 상대적으로 작아짐에 따라 소화흡수면에서 바람직하나 액정형성 시간이 길어지고, 300nm를 초과하면, 지방구의 합일이 일어날 가능성이 커지고, 소화흡수 시간이 길어지므로 바람직하지 않다. It is preferable that the diameter of the composition enclosed in such a liquid crystal film has a micro size of 100-300 nm. If the diameter is less than 100 nm, it is preferable in terms of digestion absorption as the size is relatively small, but the liquid crystal forming time is long, and if it exceeds 300 nm, the possibility of coalescence of fat spheres is increased and the digestion absorption time is long, which is not preferable.
본 발명에 따른 액정막 유화 조성물의 제조방법을 각 단계별로 상세히 설명한다. The manufacturing method of the liquid crystal film emulsion composition which concerns on this invention is demonstrated in detail for each step.
먼저, (a) 고도불포화지방산을 함유하는 유지 10 내지 80 중량부; (b) 중쇄지방산을 함유하는 유지 10 내지 80 중량부; 및 (c) 인지질이 25 내지 85 중량% 함유되어 있는 레시틴 1 내지 10 중량부를 35 내지 40℃에서 혼합하고, 질소를 투입하면서 10 내지 20분 동안 3000 내지 8000rpm으로 호모믹싱한다. First, (a) 10 to 80 parts by weight of fat or oil containing polyunsaturated fatty acids; (b) 10 to 80 parts by weight of fats and oils containing medium chain fatty acids; And (c) 1 to 10 parts by weight of lecithin containing 25 to 85% by weight of phospholipids are mixed at 35 to 40 ° C, and homomixed at 3000 to 8000 rpm for 10 to 20 minutes while adding nitrogen.
이때 가온 온도가 35℃ 미만이면 혼합이 균일하게 안 되고, 점도의 영향으로 유지와 레시틴간의 액정막의 형성이 어려워지는 문제점이 있고, 40℃를 초과하면 고도불포화지방산을 함유하는 유지의 산화가 진행되는 문제가 발생하므로 바람직하지 못하다.At this time, if the heating temperature is less than 35 ℃, the mixing is not uniform, there is a problem that it is difficult to form a liquid crystal film between the fat and oil and lecithin under the influence of viscosity, and if the temperature exceeds 40 ℃ oxidation of the fat containing polyunsaturated fatty acid proceeds It is not desirable because problems arise.
이때, 호모믹싱하는 회전속도는 3000 내지 8000rpm인 것이 바람직하며, 그 회전속도가 3000rpm 이하일 경우, 액정막의 형태가 불균일하게 되는 문제점이 있을 수 있으며, 8000rpm을 초과하는 경우 액정막의 직경이 너무 작아져 원료물질이 충분히 액정막 내부에 봉입되지 않을 수 있다. At this time, the homomixing rotational speed is preferably 3000 to 8000rpm, when the rotational speed is 3000rpm or less, there may be a problem that the shape of the liquid crystal film is non-uniform, when the diameter exceeds the 8000rpm raw material of the liquid crystal film is too small The material may not be sufficiently encapsulated inside the liquid crystal film.
그 다음, 상기 단계에서 호모믹싱된 혼합물을 마이크로플루다이저 (microfludizer)에 통과시킨다.The homomixed mixture is then passed through a microfludizer in this step.
호모믹싱된 혼합물은 마이크로플루다이저를 통과하면서 입자의 사이즈가 초미세사이즈로 작아지며, 양친매성인 인지질의 친유성 부분이 고도불포화지방산을 함유하는 유지 및 중쇄지방산을 함유하는 유지의 계면에 액정막을 형성하기 쉬워진다. 본 단계는 2회 실시되는 것이 미세액정막 형성을 위해 바람직하다. The homomixed mixture passes through the microfluidizer and the particle size is reduced to a very small size. The lipophilic portion of the amphiphilic phospholipid contains liquid crystals at the interface between fats and oils containing polyunsaturated fatty acids and fats containing heavy chain fatty acids. It becomes easy to form a film. This step is preferably performed twice for the formation of the microliquid crystal film.
마지막으로, 액정막 형성제인 글리세린지방산에스테르 1 내지 15 중량부를 첨가하여 혼합하고, 20 내지 40분 동안 호모믹싱한 후 20 내지 30℃까지 냉각시킨다. Finally, 1 to 15 parts by weight of glycerin fatty acid ester, which is a liquid crystal film forming agent, is added and mixed, homomixed for 20 to 40 minutes, and then cooled to 20 to 30 ° C.
이때, 글리세린지방산에스테르의 친유성기와 인지질의 친유성기는 서로 회합하여 안정한 미세액정막을 형성하게 된다. At this time, the lipophilic group of the glycerin fatty acid ester and the lipophilic group of the phospholipid are associated with each other to form a stable microliquid film.
상기 냉각온도가 20℃ 미만이면 점도 형성 시점이 지났기 때문에 계속 교반을 가하면 유화입자의 파괴가 발생할 수 있는 문제점이 있고, 30℃를 초과하면 점도가 형성되지 않아 제조시 규격관리가 힘든 문제점이 있다. If the cooling temperature is less than 20 ℃ since the point of forming the viscosity has passed, there is a problem that the destruction of the emulsified particles may occur if continued stirring, and if it exceeds 30 ℃ there is a problem that the standard management during manufacturing is difficult.
상기 글리세린지방산에스테르는 글리세린모노라우레이트, 글리세린모노올레이트, 폴리글리세린-2-올레이트, 폴리글리세린-2-스테아레이트, 및 이들의 혼합물로 이루어진 군으로부터 선택된 것이 바람직하다. The glycerin fatty acid ester is preferably selected from the group consisting of glycerin monolaurate, glycerin monooleate, polyglycerine-2-oleate, polyglycerine-2-stearate, and mixtures thereof.
이렇게 제조된 액정막 유화 조성물은 산화안정성이 확보되어 장기저장이 가능하고, 분산성이 증대되어 식품에 첨가시 다른 성분과의 혼합이 용이하며, 섭취시 체내에서 보다 잘 분산되어 매우 유용하게 사용될 수 있을 것으로 기대된다. The liquid crystal film emulsion composition thus prepared is secured for oxidative stability, and can be stored for a long time, and its dispersibility is increased, so that it can be easily mixed with other ingredients when added to foods, and it is more dispersed in the body when ingested and can be used very usefully. It is expected to be.
본 발명에 의한 액정막 유화 조성물은 다양한 식품에 첨가될 수 있으며, 유아용 조제분유에 첨가되는 것이 특히 바람직하다. The liquid crystal film emulsion composition according to the present invention can be added to various foods, and it is particularly preferable to add to infant formula.
이하, 본 발명의 바람직한 실시예 및 비교예를 기재한다. 그러나 하기한 실시예는 본 발명의 바람직한 일 실시예일 뿐 본 발명이 하기한 실시예에 한정되는 것은 아니다.Hereinafter, preferred examples and comparative examples of the present invention are described. However, the following examples are only one preferred embodiment of the present invention and the present invention is not limited to the following examples.
(실시예)(Example)
(실시예 1)(Example 1)
아라키돈산을 40 중량% 함유하는 미생물유래 오일 40kg(상품명:ARASCO), 카프릴산을 80 중량% 함유하는 트리글리세라이드 40kg(상품명:SEFOL), 인지질을 36 중량% 함유하는 레시틴 5kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 마이크로플루다이저에 2회 통과시킨 후 글리세린 모노라우레이트 2kg, 글리세린 모노올레이트 3kg, 폴리글리세린-2-올레이트 5kg, 폴리글리세린-2-스테아레이트 5kg을 첨가하여 30분간 호모믹싱한 후 25℃까지 냉각시켜 아라키돈산을 함유하는 액정막 유화 조성물를 제조하였다. 40 kg of microorganism-derived oil containing 40% by weight of arachidonic acid (trade name: ALASCO), 40 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), and 5 kg of lecithin containing 36% by weight of phospholipid at 35 ° C Then, homomixing was performed at 4000 rpm for 10 minutes while adding nitrogen. Pass the homomixed mixture through a microfluidizer twice, and then add 2 kg of glycerin monolaurate, 3 kg of glycerin monooleate, 5 kg of polyglycerine-2-oleate, and 5 kg of polyglycerine-2-stearate After mixing, the mixture was cooled to 25 ° C to prepare a liquid crystal film emulsion composition containing arachidonic acid.
(실시예 2) (Example 2)
DHA가 28 중량% 함유된 정제어유 40kg, 카프릴산을 80 중량% 함유하는 트리글리세라이드 40kg(상품명:SEFOL), 인지질을 36중량% 함유하는 레시틴 5kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 마이크로플루다이저에 2회 통과시킨 후 글리세린 모노라우레이트 2kg, 글리세린 모노올레이트 3kg, 폴리글리세린-2-올레이트 5kg, 폴리글리세린-2-스테아레이트 5kg을 첨가하여 30분간 호모믹싱한 후 25℃까지 냉각시켜 DHA를 함유하는 액정막 유화 조성물을 제조하였다. 40 kg of refined fish oil containing 28% by weight of DHA, 40 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), and 5 kg of lecithin containing 36% by weight of phospholipid at 35 ° C, followed by nitrogen Homomixed at 4000 rpm for 10 minutes. Pass the homomixed mixture through a microfluidizer twice, and then add 2 kg of glycerin monolaurate, 3 kg of glycerin monooleate, 5 kg of polyglycerine-2-oleate, and 5 kg of polyglycerine-2-stearate After mixing, the mixture was cooled to 25 ° C to prepare a liquid crystal film emulsion composition containing DHA.
(실시예 3) (Example 3)
EPA가 18 중량% 함유된 정제어유 60kg, 카프릴산을 80 중량% 함유하는 트리글리세라이드 30kg(상품명:SEFOL), 인지질을 36 중량% 함유하는 레시틴 3kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 마이크로플루다이저에 2회 통과시킨 후 글리세린 모노라우레이트 1kg, 글리세린 모노올레이트 1kg, 폴리글리세린-2-올레이트 3kg, 폴리글리세린-2-스테아레이트 2kg을 첨가하여 30분간 호모믹싱한 후 25℃까지 냉각시켜 EPA를 함유하는 액정막 유화 조성물을 제조하였다. 60 kg of refined fish oil containing 18% by weight of EPA, 30 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), and 3 kg of lecithin containing 36% by weight of phospholipid at 35 ° C, followed by nitrogen Homomixed at 4000 rpm for 10 minutes. Pass the homomixed mixture through a microfluidizer twice, and then add 1 kg of glycerin monolaurate, 1 kg of glycerin monooleate, 3 kg of polyglycerin-2-oleate, and 2 kg of polyglycerine-2-stearate After mixing, the mixture was cooled to 25 ° C to prepare a liquid crystal film emulsion composition containing EPA.
(실시예 4)(Example 4)
마이크로플루다이저에 1회 통과시키는 것을 제외하고, 상기 실시예 1과 동일하게 실시하였다. The same procedure as in Example 1 was conducted except that the microfluidizer was passed through once.
(실시예 5)(Example 5)
8000rpm으로 호모믹싱하는 것을 제외하고, 상기 실시예 1과 동일하게 실시하였다. Except for homomixing at 8000rpm it was carried out in the same manner as in Example 1.
(실시예 6) (Example 6)
상기 실시예 1에서 제조된 아라키돈산을 함유하는 액정막 유화 조성물을 유아용 조제분유 총중량에 대하여 10 중량%가 되도록 첨가하여 아라키돈산이 강화된 유아용 조제분유를 제조하였다. The liquid crystal film emulsion composition containing the arachidonic acid prepared in Example 1 was added to 10% by weight based on the total weight of the infant formula to prepare a infant formula fortified with arachidonic acid.
(비교예 1)(Comparative Example 1)
아라키돈산을 40 중량% 함유하는 미생물유래 오일 40kg(상품명:ARASCO), 카프릴산을 80 중량% 함유하는 트리글리세라이드 45kg(상품명:SEFOL), 인지질을 36 중량% 함유하는 레시틴 15kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 마이크로플루다이저에 1회 통과시킨 후 30분간 호모믹싱한 후 25℃까지 냉각시켜 아라키돈산을 함유하는 액정막 유화 조성물을 제조하였다. 40 kg of microorganism-derived oil containing 40% by weight of arachidonic acid (trade name: ALASCO), 45 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), and 15 kg of lecithin containing 36% by weight of phospholipids at 35 ° C Then, homomixing was performed at 4000 rpm for 10 minutes while adding nitrogen. The homomixed mixture was once passed through a microfluidizer, followed by homomixing for 30 minutes, and then cooled to 25 ° C. to prepare a liquid crystal film emulsion composition containing arachidonic acid.
(비교예 2)(Comparative Example 2)
아라키돈산을 40 중량% 함유하는 미생물유래 오일 40kg(상품명:ARASCO), 카프릴산을 80 중량% 함유하는 트리글리세라이드 45kg(상품명:SEFOL)을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 마이크로플루다이저에 1회 통과시킨 후 글리세린 모노라우레이트 2kg, 글리세린 모노올레이트 3kg, 폴리글리세린-2-올레이트 5kg, 폴리글리세린-2-스테아레이 트 5kg을 첨가하여 30분간 호모믹싱한 후 25℃까지 냉각시켜 아라키돈산을 함유하는 액정막 유화 조성물을 제조하였다. 40 kg of microorganism-derived oil containing 40% by weight of arachidonic acid (trade name: AARASCO) and 45 kg of triglyceride (trade name: SEFOL) containing 80% by weight of caprylic acid were mixed at 35 ° C, followed by 4000 rpm for 10 minutes while adding nitrogen. Homomixed. The homomixed mixture is passed through a microfluidizer once, and then 30 minutes by adding 2 kg of glycerin monolaurate, 3 kg of glycerin monooleate, 5 kg of polyglycerin-2-oleate and 5 kg of polyglycerine-2-stearate After homomixing, the mixture was cooled to 25 ° C to prepare a liquid crystal film emulsion composition containing arachidonic acid.
(비교예 3)(Comparative Example 3)
아라키돈산을 40 중량% 함유하는 미생물유래 오일 40kg(상품명:ARASCO), 카프릴산을 80 중량% 함유하는 트리글리세라이드 40kg(상품명:SEFOL), 인지질을 36 중량% 함유하는 레시틴 5kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물에 글리세린 모노라우레이트 2kg, 글리세린 모노올레이트 3kg, 폴리글리세린-2-올레이트 5kg, 폴리글리세린-2-스테아레이트 5kg을 첨가하여 30분간 호모믹싱한 후 25℃까지 냉각시켜 아라키돈산을 함유하는 액정막 유화 조성물을 제조하였다. 40 kg of microorganism-derived oil containing 40% by weight of arachidonic acid (trade name: ALASCO), 40 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), and 5 kg of lecithin containing 36% by weight of phospholipid at 35 ° C Then, homomixing was performed at 4000 rpm for 10 minutes while adding nitrogen. To the homomixed mixture, 2 kg of glycerin monolaurate, 3 kg of glycerin monooleate, 5 kg of polyglycerol-2-oleate, and 5 kg of polyglycerine-2-stearate were homomixed for 30 minutes, cooled to 25 ° C, and then arachidonic acid A liquid crystal film emulsion composition containing was prepared.
(비교예 4)(Comparative Example 4)
아라키돈산을 40 중량% 함유하는 미생물유래 오일 40kg(상품명:ARASCO), 카프릴산을 80 중량% 함유하는 트리글리세라이드 40kg(상품명:SEFOL), 인지질을 36 중량% 함유하는 레시틴 5kg, 글리세린 모노라우레이트 2kg, 글리세린 모노올레이트 3kg, 폴리글리세린-2-올레이트 5kg, 폴리글리세린-2-스테아레이트 5kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 40 kg of microorganism derived oil containing 40% by weight of arachidonic acid (trade name: ALASCO), 40 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), 5 kg of lecithin containing 36% by weight of phospholipids, glycerin monolaurate 2 kg, glycerin monooleate 3 kg, polyglycerol-2-oleate 5 kg, polyglycerin-2-stearate 5 kg were mixed at 35 ° C., followed by homomixing at 4000 rpm for 10 minutes while adding nitrogen.
(비교예 5)(Comparative Example 5)
아라키돈산을 40 중량% 함유하는 미생물유래 오일 40kg(상품명:ARASCO), 카프릴산을 80 중량% 함유하는 트리글리세라이드 40kg(상품명:SEFOL), 인지질을 36 중량% 함유하는 레시틴 5kg을 35℃에서 혼합한 다음, 질소를 투입하면서 10분간 4000rpm으로 호모믹싱하였다. 호모믹싱한 혼합물을 마이크로플루다이저에 2회 통과시킨 후 글리세린 모노라우레이트 2kg, 글리세린 모노올레이트 3kg, 폴리글리세린-2-올레이트 5kg, 폴리글리세린-2-스테아레이트 5kg을 첨가하여 30분간 호모믹싱하여 아라키돈산을 함유하는 액정막 유화 조성물을 제조하였다. 40 kg of microorganism-derived oil containing 40% by weight of arachidonic acid (trade name: ALASCO), 40 kg of triglyceride containing 80% by weight of caprylic acid (trade name: SEFOL), and 5 kg of lecithin containing 36% by weight of phospholipid at 35 ° C Then, homomixing was performed at 4000 rpm for 10 minutes while adding nitrogen. Pass the homomixed mixture through a microfluidizer twice, and then add 2 kg of glycerin monolaurate, 3 kg of glycerin monooleate, 5 kg of polyglycerine-2-oleate, and 5 kg of polyglycerine-2-stearate By mixing, a liquid crystal film emulsion composition containing arachidonic acid was prepared.
(실험예 1) Experimental Example 1
(산화안정성 측정)(Oxidation stability measurement)
산가 측정은 5g 시료를 투입한 후 에테르:에탄올이 1:1 들어 있는 용매 20ml를 투입한 후 1% 페놀프탈레인(Phenolphthalein)을 가해 0.1N 수산화칼륨(KOH)으로 적정하였고, 130℃, 20ℓ/min 통기량 조건에서 메트롬 743랜시맷(Metrohm 743 Rancimat)를 사용하여 산화 유도기간(induction time)을 측정하였다. 그 결과를 하기 표 1에 나타내었다. The acid value was measured by adding 5 g sample, adding 20 ml of solvent containing ether: ethanol 1: 1, adding 1% phenolphthalein, and titrating with 0.1 N potassium hydroxide (KOH). Oxidation induction time was measured using a Metrom 743 Rancimat under technical conditions. The results are shown in Table 1 below.
상기 표 1에서 보듯이, 비교예와 비교하여 본 발명의 방법에 따라 제조된 실시예의 산화 유도기간이 길어 산화 안정성이 높음을 확인할 수 있었다. As shown in Table 1, compared with the comparative example it was confirmed that the oxidation induction period of the embodiment prepared according to the method of the present invention has a long oxidation stability is high.
(실험예 2)Experimental Example 2
(현미경 사진)(Microscopic photo)
상기 실시예 1에서 제조된 조성물의 액정형성여부를 확인하기 위하여, 광학 현미경을 통하여 확인하여, 그 결과를 도 1에 나타내었다. 도 1에서 보이듯, 액정막이 균일하게 잘 분포됨을 확인할 수 있었다. In order to confirm the liquid crystal formation of the composition prepared in Example 1, it was confirmed through an optical microscope, the results are shown in FIG. As shown in Figure 1, it was confirmed that the liquid crystal film is uniformly well distributed.
상술한 바와 같이, 본 발명의 액정막 유화 조성물은, 고도불포화지방산의 산화안정성이 확보되어 장기저장이 가능하고, 취급이 용이하다. 또한, 분산성이 증대되어 식품에 첨가시 다른 성분과의 혼합이 용이하며, 섭취시 체내에서 보다 잘 분산되어 흡수속도를 증가시킬 수 있다. As mentioned above, the liquid-crystal film emulsion composition of this invention ensures oxidative stability of polyunsaturated fatty acid, can be stored for a long time, and is easy to handle. In addition, the dispersibility is increased to facilitate the mixing with other ingredients when added to food, it can be more dispersed in the body when ingested to increase the absorption rate.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050126658A KR100797985B1 (en) | 2005-12-21 | 2005-12-21 | Liquid crystal membrane emulsion composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050126658A KR100797985B1 (en) | 2005-12-21 | 2005-12-21 | Liquid crystal membrane emulsion composition and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20070065996A KR20070065996A (en) | 2007-06-27 |
| KR100797985B1 true KR100797985B1 (en) | 2008-01-28 |
Family
ID=38365095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050126658A KR100797985B1 (en) | 2005-12-21 | 2005-12-21 | Liquid crystal membrane emulsion composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100797985B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102096391B1 (en) * | 2019-10-11 | 2020-04-06 | (주)아이엠디팜 | Omega-3-fatty acid composition forming liquid crystal structures |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526793A (en) | 1982-04-16 | 1985-07-02 | Nestec, S.A. | Lipid composition for oral, enteral or parenteral nutrition |
| KR20030063019A (en) * | 2002-01-22 | 2003-07-28 | (주)케비젠 | Emulsive compositions comprising high unsaturated fatty acids and their preparations for micro liquid capsules |
| KR20050019770A (en) * | 2002-06-28 | 2005-03-03 | 타이요 카가꾸 가부시키가이샤 | Oil-in-water emulsion composition |
-
2005
- 2005-12-21 KR KR1020050126658A patent/KR100797985B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526793A (en) | 1982-04-16 | 1985-07-02 | Nestec, S.A. | Lipid composition for oral, enteral or parenteral nutrition |
| KR20030063019A (en) * | 2002-01-22 | 2003-07-28 | (주)케비젠 | Emulsive compositions comprising high unsaturated fatty acids and their preparations for micro liquid capsules |
| KR20050019770A (en) * | 2002-06-28 | 2005-03-03 | 타이요 카가꾸 가부시키가이샤 | Oil-in-water emulsion composition |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20070065996A (en) | 2007-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1408931B1 (en) | Isotonic lipid emulsions | |
| ES2202454T3 (en) | USE OF A BALANCING AGENT FOR OMEGA-3 AND OMEGA-6 Unsaturated FATTY ACIDS. | |
| CN107693793B (en) | Packaged compositions of hydrophilic lipid compositions, methods of preparation and formulation and uses thereof | |
| US10898442B2 (en) | Microencapsulates containing stabilised lipid, and methods for the production thereof | |
| TWI321989B (en) | Water-soluble composition containing coenzyme q10 | |
| WO2008020747A1 (en) | A method for obtaining stable micro-emulsions of derivatives of oxycarotenoids of short-chain organic acids, micro-emulsions obtained, and formulation which contains these | |
| JP5816271B2 (en) | Nutritional emulsion containing encapsulated oil | |
| JP4044354B2 (en) | Composition having alcohol resistance, acid resistance and salt resistance and uses | |
| CN106715381B (en) | Fatty acid composition and method for fortifying a nutritional product with fatty acids | |
| JPS61500432A (en) | Easily absorbable fatty acid emulsion | |
| JP6964660B2 (en) | Antioxidant dispersion | |
| WO2022061870A1 (en) | Vitamin k2 microcapsule, preparation method therefor, and application thereof in preparation of medicine for preventing and treating cardiovascular and cerebrovascular diseases | |
| JP2009027958A (en) | Emulsified substance containing astaxanthin, and method for producing the same | |
| AU629866B2 (en) | Triglycerides, nutritional composition comprising such triglycerides, and use of the nutritional composition for nutrition | |
| JPH03504868A (en) | Structured lipids containing milk fat | |
| Homroy et al. | Role of encapsulation on the bioavailability of omega‐3 fatty acids | |
| CA2331661A1 (en) | Use of 'nanofood' in foodstuff final products for humans and animals | |
| KR100797985B1 (en) | Liquid crystal membrane emulsion composition and preparation method thereof | |
| CN107568731B (en) | Coenzyme Q10 fish oil nano emulsion and preparation method and application thereof | |
| JPS63297342A (en) | Synthetic oil or fat and fatty emulsion infusion solution and tube feeding agent containing said oil or fat | |
| JP2005047851A (en) | Ubidecarenone-containing composition | |
| JPH08169824A (en) | Lipid emulsion for pediatrics | |
| CN114158732A (en) | Polyunsaturated fatty acid triglyceride microcapsule powder and preparation method thereof | |
| JP2022065087A (en) | Preparation and stabilization methods for emulsion having omega-3 by isometric crystal network of cellulose derivative | |
| JP2006056816A (en) | Fat-soluble vitamins-containing pre-emulsion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| G170 | Publication of correction | ||
| FPAY | Annual fee payment |
Payment date: 20121025 Year of fee payment: 6 |
|
| FPAY | Annual fee payment |
Payment date: 20131203 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20150116 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20160114 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20170516 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20180416 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20190107 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20200113 Year of fee payment: 13 |